An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-allylamino-17-demethoxygeldanamycin and carboplatin in human ovarian cancer models

Cancer Chemotherapy and Pharmacology
Udai BanerjiPaul Workman

Abstract

To study the interactions of the heat shock protein 90 (HSP90) inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) and carboplatin in vitro and in vivo. The combination of 17-AAG and carboplatin on the growth inhibition of A2780, SKOV-3, IGROV-1 and HX62 human ovarian cancer cells was studied in vitro by MTT assays. The effect of the sequence of administration of both drugs was further investigated in A2780 cells by sulforhodamine B assays. The ability of 17-AAG to deplete HSP90 client proteins either alone or in combination with carboplatin was evaluated by western blotting. Tumor concentrations of 17-AAG and carboplatin alone or in combination in vivo were determined by validated liquid chromatography with ultraviolet detection and atomic absorption spectroscopy methods. The growth inhibitory effects of 17-AAG, carboplatin and the combination were studied in the A2780 xenograft model. The combination index (CI) at fu(0.5) for 17-AAG plus carboplatin was 0.97 (+/-0.12 SD) when A2780 cells were exposed to carboplatin followed by 17-AAG indicating additivity. The addition of carboplatin did not alter the ability of 17-AAG to cause C-RAF, CDK4 and p-AKT depletion or HSP70 induction. Tumor 17-AAG and carboplatin concentratio...Continue Reading

References

Aug 30, 1994·Proceedings of the National Academy of Sciences of the United States of America·L WhitesellL M Neckers
Aug 1, 1994·The International Journal of Biochemistry·A HongoT Kudo
Nov 8, 1996·The Journal of Biological Chemistry·Y FangA J Caplan
Nov 21, 1997·Biochemical and Biophysical Research Communications·T W SchulteL M Neckers
Jan 23, 1999·Nature Genetics·L ShayestehJ W Gray
Jan 27, 2000·Cell·D Hanahan, R A Weinberg
May 24, 2000·The Journal of Steroid Biochemistry and Molecular Biology·A E FlissA J Caplan
Sep 20, 2000·Proceedings of the National Academy of Sciences of the United States of America·S SatoT Tsuruo
Nov 7, 2000·Gynecologic Oncology·L SuiM Tokuda
Mar 29, 2001·The Journal of Biological Chemistry·H L ForsytheS E Holt
Nov 14, 2001·Seminars in Oncology·J BaselgaJ Arribas
Jan 5, 2002·Expert Opinion on Biological Therapy·Alison Maloney, Paul Workman
Mar 22, 2002·The Lancet Oncology·D M Parkin
Apr 5, 2003·Cancer Cell·Jennifer S IsaacsLen Neckers
Jul 2, 2003·Nature Reviews. Cancer·Roshan Agarwal, Stan B Kaye
Sep 4, 2003·Journal of the National Cancer Institute·Andreas du BoisUNKNOWN Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group
Mar 3, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Giuseppe GiacconeDavid H Johnson
Mar 3, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Roy S HerbstDavid H Johnson
Jul 23, 2004·The New England Journal of Medicine·David CunninghamEric Van Cutsem
Oct 12, 2004·Drug Discovery Today·Gabriela ChiosisDavid Solit
Feb 19, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Matthew P GoetzCharles Erlichman
May 4, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ramesh K RamanathanMerrill J Egorin
Jun 18, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Udai BanerjiIan Judson
Sep 22, 2005·Nature Reviews. Cancer·Luke Whitesell, Susan L Lindquist
Oct 6, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Udai BanerjiPaul Workman
Dec 24, 2005·Proceedings of the National Academy of Sciences of the United States of America·O M GrbovicN Rosen
Mar 21, 2006·Molecular Cancer Therapeutics·Sharon SandersonSuzanne A Eccles
Apr 14, 2006·Handbook of Experimental Pharmacology·S PaceyP Workman

❮ Previous
Next ❯

Citations

Jul 11, 2013·Evidence-based Complementary and Alternative Medicine : ECAM·Ming-Shun WuYen-Chou Chen
Sep 1, 2015·Critical Reviews in Oncology/hematology·M B StopeA Mustea
Sep 8, 2009·Cancer Letters·Angela Ferrario, Charles J Gomer
Jul 29, 2011·Pediatric Blood & Cancer·Danielle C ChinnPhilip C Mack
Dec 17, 2014·International Journal of Oncology·Zuzana SolárováPeter Solár
Jan 31, 2019·Chemical Biology & Drug Design·Sona TalaeiNosratollah Zarghami
Mar 25, 2009·Chembiochem : a European Journal of Chemical Biology·Woncheol KimYoung-Soo Hong
Apr 30, 2009·British Journal of Cancer·D MahalingamF J Giles
Jul 27, 2017·Medical Gas Research·Yi-Ping DingGang Chen
Oct 5, 2016·Oncology Letters·Lovisa GöstringLars Gedda
Jan 2, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Udai Banerji
Jun 22, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Maurizio ScaltritiJavier Cortes
Apr 17, 2010·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Wouter B NagengastElisabeth G E de Vries

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.